Desmopressin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (2)

Targets (3)Enzymes (2)Biointeractions (3)

Identification

Name

Desmopressin

Accession Number

DB00035 (BTD00112, BTD00061, BIOD00112, BIOD00061)

Type

Small Molecule

Groups

Approved

Description

Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.

Structure

MOL SDF PDB SMILES InChI

Synonyms

1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin

1-deamino-8-D-arginine vasopressin

1-Desamino-8-D-arginine vasopressin

DDAVP

Desmopresina

Desmopressin

Desmopressine

Desmopressinum

Minirin

Stimate

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Desmopressin acetate	1K12647SFC	62288-83-9	MLSVJHOYXJGGTR-IFHOVBQLSA-N	Details
Desmopressin acetate trihydrate	XB13HYU18U	62357-86-2	YNKFCNRZZPFMEX-XHPDKPNGSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ddavp	Tablet	.1 mg/1	Oral	Sanofi Aventis	1995-09-06	Not applicable	US
Ddavp	Solution	4 ug/mL	Intravenous	Sanofi Aventis	1984-03-30	Not applicable	US
Ddavp	Injection	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1984-03-30	Not applicable	US
Ddavp	Tablet	.1 mg/1	Oral	Ferring Pharmaceuticals	1995-09-06	Not applicable	US
Ddavp	Tablet	.2 mg/1	Oral	Sanofi Aventis	1995-09-06	Not applicable	US
Ddavp	Solution	.1 mg/mL	Nasal	Sanofi Aventis	1978-02-21	Not applicable	US
Ddavp	Injection	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1984-03-30	Not applicable	US
Ddavp	Tablet	.2 mg/1	Oral	Ferring Pharmaceuticals	1995-09-06	Not applicable	US
Ddavp	Spray	.1 ug/mL	Nasal	Ferring Pharmaceuticals	1978-02-21	Not applicable	US
Ddavp	Spray	.1 ug/mL	Nasal	Ferring Pharmaceuticals	1978-02-21	Not applicable	US
Ddavp Inj 4mcg/ml	Liquid	4 mcg	Intramuscular; Intravenous; Subcutaneous	Ferring Pharmaceuticals	1993-12-31	Not applicable	Canada
Ddavp Melt	Tablet, orally disintegrating	120 mcg	Sublingual	Ferring Pharmaceuticals	2006-11-02	Not applicable	Canada
Ddavp Melt	Tablet, orally disintegrating	60 mcg	Sublingual	Ferring Pharmaceuticals	2006-11-02	Not applicable	Canada
Ddavp Melt	Tablet, orally disintegrating	240 mcg	Sublingual	Ferring Pharmaceuticals	2009-05-05	Not applicable	Canada
Ddavp Rhinal Tube	Solution	.1 mg/mL	Nasal	Sanofi Aventis	1978-02-21	Not applicable	US
Ddavp Rhinyle	Solution	0.1 mg	Nasal	Ferring Pharmaceuticals	1992-12-31	Not applicable	Canada
Ddavp Spray	Aerosol, metered	10 mcg	Nasal	Ferring Pharmaceuticals	1989-12-31	Not applicable	Canada
Ddavp Tablets 0.1mg	Tablet	0.1 mg	Oral	Ferring Pharmaceuticals	1995-12-31	Not applicable	Canada
Ddavp Tablets 0.2mg	Tablet	0.2 mg	Oral	Ferring Pharmaceuticals	1995-12-31	Not applicable	Canada
Desmopressin	Tablet	0.1 mg	Oral	Meliapharm Inc	2011-07-27	2014-06-25	Canada
Desmopressin	Tablet	0.2 mg	Oral	Meliapharm Inc	2011-07-27	2014-06-25	Canada
Desmopressin Acetate	Spray	10 ug/.1mL	Nasal	Amring Pharmaceuticals, Inc.	2016-03-01	Not applicable	US
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Ferring Pharmaceuticals	1999-08-10	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Ferring Pharmaceuticals	2008-05-05	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Amring Pharmaceuticals, Inc.	2008-05-05	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Ferring Pharmaceuticals	2008-05-05	Not applicable	US
Desmopressin Acetate	Solution	4 ug/mL	Intravenous	Amring Pharmaceuticals, Inc.	1999-10-26	Not applicable	US
Desmopressin Acetate	Spray	10 ug/.1mL	Nasal	Prasco, Laboratories	2014-01-01	Not applicable	US
Desmopressin Acetate	Solution	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1999-10-26	Not applicable	US
Desmopressin Acetate	Solution	4 ug/mL	Intravenous	Amring Pharmaceuticals, Inc.	1999-10-26	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Amring Pharmaceuticals, Inc.	2008-05-05	Not applicable	US
Desmopressin Acetate	Solution	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1999-10-26	Not applicable	US
Desmopressin Spray	Spray, metered	10 mcg	Nasal	Aa Pharma Inc	2000-08-18	Not applicable	Canada
Desmopressin Tablets	Tablet	0.2 mg	Oral	Rainbow Pharmaceuticals Inc	2005-02-18	2012-08-03	Canada
Desmopressin Tablets	Tablet	0.1 mg	Oral	Rainbow Pharmaceuticals Inc	2005-02-18	2012-08-03	Canada
Minirin	Tablet	0.1 mg	Oral	Ferring Pharmaceuticals	2003-01-15	2015-07-22	Canada
Minirin	Aerosol, metered	10 mcg	Nasal	Ferring Pharmaceuticals	2000-08-21	2005-08-02	Canada
Nocdurna	Tablet, orally disintegrating	50 mcg	Sublingual	Ferring Pharmaceuticals	2014-11-17	Not applicable	Canada
Nocdurna	Tablet, orally disintegrating	25 mcg	Sublingual	Ferring Pharmaceuticals	2013-07-31	Not applicable	Canada
Nu-desmopressin Spray	Spray, metered	0.1 g	Nasal	Nu Pharm Inc	Not applicable	Not applicable	Canada
Octostim Liq Inj. 15mcg/ml	Liquid	15 mcg	Intravenous; Subcutaneous	Ferring Pharmaceuticals	1995-12-31	Not applicable	Canada
Octostim Spray	Spray	150 mcg	Nasal	Ferring Pharmaceuticals	1998-12-01	Not applicable	Canada
PMS-desmopressin	Tablet	0.1 mg	Oral	Pharmascience Inc	2008-01-23	Not applicable	Canada
PMS-desmopressin	Tablet	0.2 mg	Oral	Pharmascience Inc	2008-01-23	Not applicable	Canada
Stimate	Spray, metered	1.5 mg/mL	Nasal	Csl Behring	2011-09-16	Not applicable	US
Teva-desmopressin	Tablet	0.1 mg	Oral	Teva	2007-07-16	Not applicable	Canada
Teva-desmopressin	Tablet	0.2 mg	Oral	Teva	2007-07-16	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-desmopressin	Tablet	0.2 mg	Oral	Apotex Corporation	2007-01-31	Not applicable	Canada
Apo-desmopressin	Tablet	0.1 mg	Oral	Apotex Corporation	2007-01-31	Not applicable	Canada
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Heritage	2014-08-14	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Av Pak	2013-07-24	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Blue Point Laboratories	2014-02-27	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Apotex Corporation	2006-03-07	Not applicable	US
Desmopressin Acetate	Injection, solution	4 ug/mL	Intravenous; Subcutaneous	Hospira, Inc.	2000-08-28	Not applicable	US
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Physicians Total Care, Inc.	2006-05-22	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Amerincan Health Packaging	2010-01-12	2015-12-29	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-01-17	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Amerincan Health Packaging	2015-09-15	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Amerincan Health Packaging	2012-10-08	2017-03-31	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Physicians Total Care, Inc.	2007-07-19	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2015-05-28	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Blue Point Laboratories	2017-04-30	Not applicable	US
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Bauch & Lomb Incorporated	1999-01-25	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	bryant ranch prepack	2011-08-15	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Teva	2006-01-27	2017-12-31	US
Desmopressin Acetate	Spray	10 ug/1	Nasal	Apotex Corporation	2005-01-27	2017-02-23	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Amerincan Health Packaging	2010-01-12	2015-12-29	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Heritage	2014-08-14	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Av Pak	2013-07-24	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Carilion Materials Management	2006-01-27	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Apotex Corporation	2006-03-07	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Actavis Pharma Company	2011-08-15	Not applicable	US
Desmopressin Acetate	Injection	4 ug/mL	Intravenous	Teva Parenteral Medicines, Inc.	1997-11-01	Not applicable	US
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Sun Pharmaceutical Industries Limited	2012-04-14	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Impax Generics	2006-01-27	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Blue Point Laboratories	2014-02-27	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Teva	2006-01-27	2017-12-31	US
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Sun Pharma Global FZE	2013-12-24	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Actavis Pharma Company	2011-08-15	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Amerincan Health Packaging	2015-09-15	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Amerincan Health Packaging	2012-10-08	2017-03-31	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Mylan Institutional	2007-12-26	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2015-05-28	Not applicable	US
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Blue Point Laboratories	2017-04-30	Not applicable	US
Desmopressin Acetate	Injection	4 ug/mL	Intravenous	Teva Parenteral Medicines, Inc.	1997-11-01	Not applicable	US
Desmopressin Acetate	Injection, solution	4 ug/mL	Intravenous; Subcutaneous	Sun Pharmaceutical Industries Limited	2013-01-30	Not applicable	US
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Impax Generics	2006-01-27	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Adiuretin	Ferring
DesmoMelt	Ferring

Brand mixtures

Not Available

Categories

UNII

ENR1LLB0FP

CAS number

16679-58-6

Weight

Average: 1069.217
Monoisotopic: 1068.426954962

Chemical Formula

C₄₆H₆₄N₁₄O₁₂S₂

InChI Key

NFLWUMRGJYTJIN-NXBWRCJVSA-N

InChI

InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1

IUPAC Name

(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide

SMILES

NC(=O)CC[C@@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O

Pharmacology

Indication

Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia.

Structured Indications

Pharmacodynamics

Desmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting.

Mechanism of action

Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Vasopressin V2 receptor	Protein	yes	agonist	Human	P30518	details
Vasopressin V1a receptor	Protein	yes	Not Available	Human	P37288	details
Vasopressin V1b receptor	Protein	yes	Not Available	Human	P47901	details

Absorption

Minimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa.

Volume of distribution

Not Available

Protein binding

50%

Metabolism

Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes.

Route of elimination

Not Available

Half life

Oral t_1/2=1.5-2.5 hours. Intranasal t_1/2=3.3-3.5 hours. IV t_1/2 is biphasic: initial t_1/2=7.8 minutes, terminal t_1/2=0.4-4 hours.

Clearance

Not Available

Toxicity

Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.	Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.	Approved, Illicit
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.	Experimental, Illicit
Amineptine	The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.	Illicit, Withdrawn
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Acetovanillone is combined with Desmopressin.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.	Approved, Investigational
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.	Approved, Investigational
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.	Withdrawn
Betulinic Acid	The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desmopressin.	Investigational
Bezitramide	The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.	Experimental, Illicit, Withdrawn
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.	Investigational
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.	Approved, Illicit, Investigational, Vet Approved
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.	Approved, Illicit, Vet Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.	Approved, Investigational
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.	Illicit, Vet Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.	Approved, Vet Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.	Approved, Vet Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.	Approved
Citalopram	The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.	Approved
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.	Approved, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.	Approved
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.	Approved, Illicit
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.	Investigational
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.	Investigational
Demeclocycline	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.	Approved
Desvenlafaxine	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.	Approved, Vet Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.	Experimental, Illicit
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.	Approved, Illicit
Dosulepin	The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.	Approved
Duloxetine	The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E6201 is combined with Desmopressin.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Ebselen is combined with Desmopressin.	Investigational
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.	Approved
Escitalopram	The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.	Approved, Investigational
Esmirtazapine	The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.	Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.	Approved, Investigational
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.	Approved, Illicit
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.	Illicit, Vet Approved
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.	Approved, Illicit, Investigational, Vet Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.	Approved, Withdrawn
Fluoxetine	The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.	Approved, Vet Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.	Approved, Investigational
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.	Approved, Investigational
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.	Approved, Illicit
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.	Investigational
Hydrocodone	The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.	Approved, Illicit
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.	Investigational, Withdrawn
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.	Withdrawn
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.	Withdrawn
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.	Experimental
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.	Approved
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.	Approved
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.	Investigational
Lithium	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.	Illicit
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.	Approved, Investigational
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.	Approved, Vet Approved
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.	Withdrawn
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.	Approved
Mirtazapine	The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.	Investigational
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.	Approved, Vet Approved
NCX 4016	The risk or severity of adverse effects can be increased when NCX 4016 is combined with Desmopressin.	Investigational
Nefazodone	The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.	Approved, Withdrawn
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.	Approved
Opipramol	The risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.	Investigational
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.	Approved, Illicit
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.	Approved, Investigational, Vet Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.	Withdrawn
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.	Approved, Vet Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.	Approved, Investigational
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.	Investigational
Piritramide	The risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.	Approved, Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.	Approved
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.	Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.	Experimental, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.	Investigational, Withdrawn
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.	Approved
Sertraline	The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.	Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.	Approved, Investigational
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.	Approved, Withdrawn
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.	Approved
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.	Approved
Tianeptine	The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.	Approved
Tolvaptan	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.	Approved, Investigational
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.	Approved, Investigational
Trimipramine	The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.	Investigational, Withdrawn
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.	Approved, Investigational, Withdrawn
Zimelidine	The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.	Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.

US5674850

General References

Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14260
KEGG Drug	D00291
KEGG Compound	C06944
PubChem Compound	16051933
PubChem Substance	46507014
ChemSpider	10481973
BindingDB	50205291
ChEBI	4450
ChEMBL	CHEMBL376685
Therapeutic Targets Database	DNC000526
PharmGKB	PA449237
Drug Product Database	2155
RxList	http://www.rxlist.com/cgi/generic3/desmoprt.htm
Drugs.com	http://www.drugs.com/cdi/desmopressin.html
Wikipedia	Desmopressin

ATC Codes

H01BA02 — Desmopressin

AHFS Codes

68:28.00

PDB Entries

Not Available

FDA label

Download (90.1 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Dyspnea / Haemorrhage / Tachycardia	1
1	Completed	Treatment	Hypertensive	1
1	Enrolling by Invitation	Diagnostic	Hemophilia A	1
2	Completed	Not Available	Cancer, Breast	1
2	Completed	Treatment	Intracerebral Hemorrhage	1
2	Completed	Treatment	Nocturia	1
2	Not Yet Recruiting	Treatment	Nocturia	1
2	Recruiting	Other	Colorectal Cancers / Rectal haemorrhage	1
2	Terminated	Treatment	Nocturia	1
2	Unknown Status	Treatment	Postoperative Ecchymosis	1
2, 3	Terminated	Treatment	Leptospirosis	1
2, 3	Terminated	Treatment	Nocturia	1
3	Completed	Treatment	Central Diabetes Insipidus	1
3	Completed	Treatment	Nocturia	5
3	Completed	Treatment	Nocturnal Enuresis	2
3	Completed	Treatment	Primary Nocturnal Enuresis	1
3	Recruiting	Treatment	Nocturia	2
3	Recruiting	Treatment	Nocturnal Enuresis / Sickle Cell Disorders	1
3	Terminated	Treatment	Nocturia / Obstructive Sleep Apnoea (OSA)	1
3	Unknown Status	Treatment	Pain / Renal Colic	1
4	Completed	Prevention	Blood Loss,Surgical / Hemorrhage / Postoperative Hemorrhages	1
4	Completed	Prevention	Patients Undergoing Endoscopic Sinus Surgery	1
4	Completed	Prevention	Renal Failure	1
4	Completed	Treatment	Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis / Heye´s Syndrome / Severe Aortic Stenosis	1
4	Completed	Treatment	Enuresis / Polyuria	1
4	Completed	Treatment	Nocturia	1
4	Completed	Treatment	Nocturnal Polyuria	1
4	Completed	Treatment	Primary Nocturnal Enuresis	1
4	Recruiting	Diagnostic	Monosymptomatic Nocturnal Enuresis	1
4	Terminated	Treatment	Hemorrhage / Postoperative Blood Loss	1
4	Terminated	Treatment	Parkinson's Disease (PD)	1
4	Unknown Status	Treatment	Hypothermia Induced Impairment of Primary Haemostasis	1
4	Unknown Status	Treatment	Nocturia	1
4	Unknown Status	Treatment	Nocturnal Enuresis	1
Not Available	Completed	Not Available	Head Injury Trauma Blunt	1
Not Available	Completed	Not Available	Nocturia Associated With Nocturnal Polyuria	1
Not Available	Completed	Not Available	Platelets Dysfunction	1
Not Available	Completed	Basic Science	Gender Difference in V2 Receptor Function in Response to dDAVP Infusion / Nocturia / Nocturnal Enuresis	1
Not Available	Completed	Prevention	Blood Platelet Disorders / Disorders, Blood Coagulation / Hematologic Diseases / Hypermenorrhea / Von Willebrand 's disease Type 1	1
Not Available	Completed	Screening	Diabetes Insipidus / Diabetes Insipidus, Neurohypophyseal	1
Not Available	Completed	Treatment	Coagulation Disorders / Liver Cirrhosis	1
Not Available	Completed	Treatment	Desmopressin / Hemodilution / Mild Hypothermia / NSAIDs / Platelets Dysfunction	1
Not Available	Completed	Treatment	Renal Colic	1
Not Available	Recruiting	Not Available	Nocturia	1
Not Available	Unknown Status	Not Available	Acquired Haemophilia	1
Not Available	Unknown Status	Screening	Diabetes Insipidus	1
Not Available	Unknown Status	Treatment	Idiopathic Scoliosis	1

Pharmacoeconomics

Manufacturers

Sanofi aventis us llc
Bedford laboratories div ben venue laboratories inc
Hospira inc
Teva parenteral medicines inc
Ferring pharmaceuticals inc
Bausch and lomb pharmaceuticals inc
Apotex inc richmond hill
Csl behring llc
Apotex inc etobicoke site
Teva pharmaceuticals usa
Watson laboratories inc

Packagers

Dosage forms

Form	Route	Strength
Solution	Intravenous	4 ug/mL
Spray	Nasal	.1 ug/mL
Tablet	Oral	.1 mg/1
Tablet	Oral	.2 mg/1
Liquid	Intramuscular; Intravenous; Subcutaneous	4 mcg
Tablet, orally disintegrating	Sublingual	120 mcg
Tablet, orally disintegrating	Sublingual	240 mcg
Tablet, orally disintegrating	Sublingual	60 mcg
Solution	Nasal	.1 mg/mL
Solution	Nasal	0.1 mg
Aerosol, metered	Nasal	10 mcg
Tablet	Oral	0.1 mg
Tablet	Oral	0.2 mg
Injection	Intravenous	4 ug/mL
Injection, solution	Intravenous; Subcutaneous	4 ug/mL
Spray	Nasal	10 ug/1
Spray	Nasal	10 ug/.1mL
Spray, metered	Nasal	10 mcg
Tablet, orally disintegrating	Sublingual	25 mcg
Tablet, orally disintegrating	Sublingual	50 mcg
Spray, metered	Nasal	0.1 g
Liquid	Intravenous; Subcutaneous	15 mcg
Spray	Nasal	150 mcg
Spray, metered	Nasal	1.5 mg/mL

Prices

Unit description	Cost	Unit
Stimate 1.5 mg/ml nasal spray	334.2USD	ml
Ddavp 0.01% nasal spray	50.76USD	ml
Ddavp 4 mcg/ml ampul	43.27USD	ml
Desmopressin 0.1 mg/ml spray	39.6USD	ml
Ddavp 0.1 mg/ml Solution	21.26USD	ml
Octostim 150 mcg/dose Metered Dose Spray	17.39USD	dose
Ddavp 4 mcg/ml	11.33USD	ml
Desmopressin ac 4 mcg/ml amp	7.28USD	ml
Desmopressin ac 4 mcg/ml vial	7.08USD	ml
Ddavp 0.2 mg tablet	6.43USD	tablet
Ddavp 0.1 mg tablet	4.47USD	tablet
Desmopressin acetate 0.2 mg tablet	4.44USD	tablet
Desmopressin acetate 0.1 mg tablet	3.08USD	tablet
Ddavp 0.2 mg Tablet	2.98USD	tablet
Ddavp 10 mcg/dose Metered Dose Spray	2.13USD	dose
Apo-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Novo-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Pms-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Ddavp 0.1 mg Tablet	1.49USD	tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray	1.48USD	dose
Apo-Desmopressin 0.1 mg Tablet	0.83USD	tablet
Novo-Desmopressin 0.1 mg Tablet	0.83USD	tablet
Pms-Desmopressin 0.1 mg Tablet	0.83USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2484724	No	2007-01-16	2023-05-07	Canada
CA2486833	No	2005-08-02	2024-04-30	Canada
US5500413	No	1993-06-29	2013-06-29	US
US7022340	No	2003-04-30	2023-04-30	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	-4.2	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.11 mg/mL	ALOGPS
logP	-1	ALOGPS
logP	-6.1	ChemAxon
logS	-4	ALOGPS
pKa (Strongest Acidic)	9.5	ChemAxon
pKa (Strongest Basic)	11.77	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	15	ChemAxon
Hydrogen Donor Count	14	ChemAxon
Polar Surface Area	435.41 Å²	ChemAxon
Rotatable Bond Count	19	ChemAxon
Refractivity	279.78 m³·mol^-1	ChemAxon
Polarizability	106.19 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.7979
Blood Brain Barrier	-	0.8866
Caco-2 permeable	-	0.7612
P-glycoprotein substrate	Substrate	0.8242
P-glycoprotein inhibitor I	Non-inhibitor	0.7864
P-glycoprotein inhibitor II	Non-inhibitor	0.9237
Renal organic cation transporter	Non-inhibitor	0.5915
CYP450 2C9 substrate	Non-substrate	0.7833
CYP450 2D6 substrate	Non-substrate	0.7901
CYP450 3A4 substrate	Non-substrate	0.5497
CYP450 1A2 substrate	Non-inhibitor	0.8383
CYP450 2C9 inhibitor	Non-inhibitor	0.7906
CYP450 2D6 inhibitor	Non-inhibitor	0.8735
CYP450 2C19 inhibitor	Non-inhibitor	0.765
CYP450 3A4 inhibitor	Non-inhibitor	0.7663
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9331
Ames test	Non AMES toxic	0.6679
Carcinogenicity	Non-carcinogens	0.8428
Biodegradation	Not ready biodegradable	0.9445
Rat acute toxicity	2.7183 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.83
hERG inhibition (predictor II)	Inhibitor	0.6036

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic acids and derivatives

Sub Class

Carboxylic acids and derivatives

Direct Parent

Oligopeptides

Alternative Parents

Cyclic peptides / Arginine and derivatives / Proline and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives

Substituents

Alpha-oligopeptide / Cyclic alpha peptide / Arginine or derivatives / N-acyl-alpha amino acid or derivatives / Proline or derivatives / Macrolactam / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / N-acylpyrrolidine

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

Not Available

Targets

Details

1. Vasopressin V2 receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Vasopressin receptor activity
Specific Function:: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:: AVPR2
Uniprot ID:: P30518
Molecular Weight:: 40278.57 Da

References

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325 ]
Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Vasopressin V1a receptor

Kind: Protein
Organism: Human
Pharmacological action: yes

General Function:: Vasopressin receptor activity
Specific Function:: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:: AVPR1A
Uniprot ID:: P37288
Molecular Weight:: 46799.105 Da

References

Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046 ]
Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321 ]
Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254 ]
Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]

Details

3. Vasopressin V1b receptor

Kind: Protein
Organism: Human
Pharmacological action: yes

General Function:: Vasopressin receptor activity
Specific Function:: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name:: AVPR1B
Uniprot ID:: P47901
Molecular Weight:: 46970.345 Da

References

Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460 ]
Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638 ]
Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906 ]

Enzymes

Details

1. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:: PTGS1
Uniprot ID:: P23219
Molecular Weight:: 68685.82 Da

References

Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]

Details

2. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:: PTGS2
Uniprot ID:: P35354
Molecular Weight:: 68995.625 Da

References

Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:45

Get DrugBank to go!

Structure for DB00035 (Desmopressin)

Targets

References

References

References

Enzymes

References

References